comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 01:01:04 - browse：7

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Sanofi CEO defends move to abandon profit guidance, boost research

WSS

Shifting the focus from loneliness to social health

FDA approves Recor Medical high blood pressure device

Woman returns to dialysis after doctors remove transplanted pig kidney

Letters to First Opinion on caregivers, digital health, and more

Will General Catalyst be the first of many hospital takeovers?

Senate panel clears PBM, hopsital reforms

focus

comprehensive

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

How to increase colonoscopy rates? Looks like an AI can help

Moonlake's readout produced a cash windfall. Risks remain

Woman returns to dialysis after doctors remove transplanted pig kidney

Wildfire smoke exposes gaps in outdoor worker protections

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Psychedelics group wrestles with new pharma identity

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Activists slam private health insurers over coverage restrictions

HIV drugs protect against transmission, even in unprotected sex

hotspot

More doctors should go into startup world

Ionis drug prevents swelling attacks due to hereditary angioedema

White House calls on federal agencies to crack down on AI abuses

HPV cancer vaccine study demonstrates efficacy

The Sacklers, horror, and ‘The Fall of the House of Usher’

UCSF medical school apologizes for unethical prisoner experiments

hotspot

hotspot

focus

leisure time